Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Amalgamated Bank

Amalgamated Bank increased its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 30.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,274 shares of the company’s stock after buying an additional 295 shares during the quarter. Amalgamated Bank’s holdings in Tarsus Pharmaceuticals were worth $65,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TARS. Bank of New York Mellon Corp grew its holdings in Tarsus Pharmaceuticals by 0.5% in the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company’s stock worth $5,644,000 after buying an additional 498 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Tarsus Pharmaceuticals by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 293,700 shares of the company’s stock valued at $16,262,000 after purchasing an additional 3,691 shares in the last quarter. Victory Capital Management Inc. bought a new position in Tarsus Pharmaceuticals during the 4th quarter valued at $223,000. Raymond James Financial Inc. bought a new position in Tarsus Pharmaceuticals during the 4th quarter valued at $1,107,000. Finally, HighTower Advisors LLC bought a new position in Tarsus Pharmaceuticals during the 4th quarter valued at $207,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Down 4.8%

TARS stock opened at $39.18 on Friday. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a market cap of $1.65 billion, a PE ratio of -14.35 and a beta of 0.80. The business’s 50-day simple moving average is $42.36 and its 200 day simple moving average is $47.07. The company has a quick ratio of 5.54, a current ratio of 5.57 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. The firm had revenue of $78.34 million during the quarter, compared to analysts’ expectations of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. On average, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TARS shares. Oppenheimer began coverage on Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They set an “outperform” rating and a $75.00 price target for the company. HC Wainwright upgraded Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 target price for the company in a report on Tuesday, May 27th. Guggenheim increased their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. The Goldman Sachs Group raised their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a “neutral” rating in a report on Monday, May 5th. Finally, Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $66.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.